Immunoglobulin in chronic inflammatory diseases.
Several case studies are presented to illustrate the success of intravenous gammaglobulin (IVIG) therapy in ulcerative colitis, Crohn's disease, chronic anterior uveitis, herpes zoster, and relapsing genital herpes simplex. Hypothetical mechanisms explain the marked improvement of the chronic disorders, with particular emphasis on substitution of specific antibodies. The recently recognized heterogeneity of the major histocompatibility complex (MHC) is explored as one possible explanation for low and high responders to particular antigens. It is suggested that various chronic inflammatory disorders result from ineffective immune responses, and that the administration of IVIG may shift the delicate balance between the pathogen and the host to favor the latter.
D000328:Adult; D002908:Chronic Disease / Q000188:drug therapy* / Q000276:immunology; D003093:Colitis, Ulcerative / Q000188:drug therapy; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D015796:HLA-B27 Antigen; D006558:Herpes Genitalis / Q000188:drug therapy; D000949:Histocompatibility Antigens Class II; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007116:Immunization, Passive; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology; D007275:Injections, Intravenous; D008285:Major Histocompatibility Complex; D008875:Middle Aged; D013166:Spondylitis / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D006680:HLA Antigens; D015796:HLA-B27 Antigen; D000949:Histocompatibility Antigens Class II